Status:
COMPLETED
Genetic Determinants of Response to Neoadjuvant Cisplatin-based Chemotherapy in Urothelial Cancer
Lead Sponsor:
University of Chicago
Conditions:
Urothelial Cancer
Eligibility:
All Genders
18-89 years
Brief Summary
This is observational clinical trial to study adult urothelial cancer patients treated with cisplatin-based neoadjuvant chemotherapy. Hypothesis: Identification of genetic and molecular "cisplatin su...
Detailed Description
In this trial patients will submit germline (blood) and tumor tissue samples as part of two existing sample collection protocols for analysis of genetic and molecular markers governing response to che...
Eligibility Criteria
Inclusion
- Patients with clinical T2 through T4 urothelial carcinoma of the bladder or upper tract.
- Patients must be deemed appropriate by the treating physician to require cisplatin-based neoadjuvant chemotherapy for urothelial cancer. Consideration of regional nodal status as part of the decision for appropriateness for neoadjuvant chemotherapy will be left to the treating physician.
- Patients must be scheduled to proceed to definitive urothelial cancer surgery, including either cystectomy or nephrectomy/ureterectomy, after chemotherapy.
- Age \>18 years.
Exclusion
- Patients receiving cisplatin-based chemotherapy for urothelial cancer in the adjuvant setting or for metastatic disease.
Key Trial Info
Start Date :
October 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 16 2017
Estimated Enrollment :
79 Patients enrolled
Trial Details
Trial ID
NCT01206426
Start Date
October 1 2009
End Date
October 16 2017
Last Update
May 4 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Chicago
Chicago, Illinois, United States, 60637